keyword
https://read.qxmd.com/read/38128247/beyond-the-binary-characterizing-the-relationships-between-sex-and-neuropeptide-receptor-binding-density-measures-in-the-rat-brain
#61
JOURNAL ARTICLE
Daphna Joel, Caroline J Smith, Alexa H Veenema
Sex differences exist in numerous parameters of the brain. Yet, sex-related factors are part of a large set of variables that interact to affect many aspects of brain structure and function. This raises questions regarding how to interpret findings of sex differences at the level of single brain measures and the brain as a whole. In the present study, we reanalyzed two datasets consisting of measures of oxytocin, vasopressin V1a, and mu opioid receptor binding densities in multiple brain regions in rats. At the level of single brain measures, we found that sex differences were rarely dimorphic and were largely persistent across estrous stage and parental status but not across age or context...
December 20, 2023: Hormones and Behavior
https://read.qxmd.com/read/38124015/neural-network-connectivity-following-opioid-dependence-is-altered-by-a-common-genetic-variant-in-the-mu-opioid-receptor-oprm1-a118g
#62
JOURNAL ARTICLE
Yihan Xie, Julia K Brynildsen, Kyle Windisch, Julie A Blendy
Opioid use disorder is a chronic, relapsing disease associated with persistent changes in brain plasticity. A common single nucleotide polymorphism (SNP) in the mu-opioid receptor gene, OPRM1 A118G, is associated with altered vulnerability to opioid addiction. Reconfiguration of neuronal connectivity may explain dependence risk in individuals with this SNP. Mice with the equivalent Oprm1 variant, A112G, demonstrate sex-specific alterations in the rewarding properties of morphine and heroin. To determine whether this SNP influences network-level changes in neuronal activity we compared FOS expression in male and female mice that were opioid-naïve or opioid-dependent...
December 8, 2023: Journal of Neuroscience
https://read.qxmd.com/read/38103700/similarities-and-differences-in-peripheral-itch-and-pain-pathways-in-atopic-dermatitis
#63
REVIEW
Gil Yosipovitch, Brian Kim, Thomas Luger, Ethan Lerner, Martin Metz, Roni Adiri, Juliana M Canosa, Amy Cha, Sonja Ständer
Atopic dermatitis (AD) is predominantly characterized by intense itching, but concomitant skin pain is experienced by more than 40% of patients. Patients with AD display considerable somatosensory aberrations including increased nerve sensitivity to itch stimuli (hyperknesis), perception of itch from innocuous stimuli (alloknesis), or perception of pain from innocuous stimuli (allodynia). This review summarizes the current understanding of the similarities and differences in the peripheral mechanisms underlying itch and pain in atopic dermatitis...
December 14, 2023: Journal of Allergy and Clinical Immunology
https://read.qxmd.com/read/38099284/epigenetic-regulation-in-opioid-induced-hyperalgesia
#64
REVIEW
Deepa Reddy, Jason R Wickman, Seena K Ajit
About 25 million American adults experience pain daily and one of the most commonly prescribed drugs to treat pain are opioids. Prolonged opioid usage and dose escalations can cause a paradoxical response where patients experience enhanced pain sensitivity. This opioid induced hyperalgesia (OIH) is a major hurdle when treating pain in the clinic because its underlying mechanisms are still not fully understood. OIH is also commonly overlooked and lacks guidelines to prevent its onset. Research on pain disorders and opioid usage have recognized potential epigenetic drivers of disease including DNA methylation, histone modifications, miRNA regulation, but their involvement in OIH has not been well studied...
2023: Neurobiology of Pain
https://read.qxmd.com/read/38099236/kappa-opioid-agonists-in-the-treatment-of-itch-just-scratching-the-surface
#65
JOURNAL ARTICLE
Tyler C Beck, Elena M Wilson, Erik Wilkes, Lara Wine Lee, Russell Norris, Manuel Valdebran
Chronic pruritus is a debilitating condition affecting 23-44 million Americans. Recently, kappa opioid agonists (KOAs) have emerged as a novel class of potent antipruritic agents. In 2021, the Food and Drug Administration approved difelikefalin (Korsuva) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Difelikefalin is a potent, peripherally restricted KOA that is intravenously available. Although promising, difelikefalin is currently available as an intravenous composition only, limiting the scope of use...
2023: Itch
https://read.qxmd.com/read/38094140/intravenous-methadone-in-the-management-of-acute-postoperative-pain-in-a-chronic-cancer-pain-patient-a-case-report-and-review-of-the-literature
#66
Khang Duy Ricky Le, Jean Hua
KEY CLINICAL MESSAGE: The current landscape of literature highlights that there is insufficient well-powered and robust evidence to support the integration of intravenous methadone into current guidelines and frameworks in supporting the pain management of cancer patient with complex pain syndromes. However, there is preliminary evidence, both from the literature as well as this case study that highlights intravenous methadone may be efficaciously and safety used for the management of postoperative pain in cancer patients with chronic pain undergoing operative management...
December 2023: Clinical Case Reports
https://read.qxmd.com/read/38081336/iuphar-review-recent-progress-in-the-development-of-mu-opioid-receptor-modulators-to-treat-opioid-use-disorders
#67
JOURNAL ARTICLE
Piyusha P Pagare, Rachael Flammia, Yan Zhang
Opioid Use Disorder (OUD) can be described as intense preoccupation with using or obtaining opioids despite the negative consequences associated with their use. As the number of OUD cases in the U.S. increase, so do the number of opioid-related overdose deaths. In 2022, opioid-related overdose became the No. 1 cause of death for individuals in the U.S. between the ages of 25 and 64 years of age. Because of the introduction of highly potent synthetic opioids (e.g. fentanyl) to the illicit drug market, there is an urgent need for therapeutics that successfully reduce the number of overdoses and can help OUD patients maintain sobriety...
January 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38077082/mu-opioid-receptor-knockout-on-foxp2-expressing-neurons-leads-to-reduced-aversion-resistant-reward-seeking
#68
Harrison M Carvour, Charlotte A E G Roemer, D'Erick P Underwood, Edith Padilla, Oscar Sandoval, Megan Robertson, Mallory Miller, Natella Parsadanyan, Thomas W Perry, Anna K Radke
Mu-opioid receptors (MORs) in the amygdala and striatum are important in addictive and rewarding behaviors. Foxp2 is a marker of intercalated (ITC) cells in the amygdala and a subset of striatal medium spiny neurons (MSNs), both of which express MORs in wild-type mice. For the current series of studies, we characterized the behavior of mice with genetic deletion of the MOR gene Oprm1 in Foxp2-expressing neurons (Foxp2-Cre/Oprm1 fl/fl ). Male and female Foxp2-Cre/Oprm1 fl/fl mice were generated and heterozygous Cre+ (knockout) and homozygous Cre-(control) animals were tested for aversion-resistant alcohol consumption using an intermittent access (IA) task, operant responding for a sucrose reward, conditioned place aversion (CPA) to morphine withdrawal, and locomotor sensitization to morphine...
December 1, 2023: bioRxiv
https://read.qxmd.com/read/38052802/design-and-structural-validation-of-peptide-drug-conjugate-ligands-of-the-kappa-opioid-receptor
#69
JOURNAL ARTICLE
Edin Muratspahić, Kristine Deibler, Jianming Han, Nataša Tomašević, Kirtikumar B Jadhav, Aina-Leonor Olivé-Marti, Nadine Hochrainer, Roland Hellinger, Johannes Koehbach, Jonathan F Fay, Mohammad Homaidur Rahman, Lamees Hegazy, Timothy W Craven, Balazs R Varga, Gaurav Bhardwaj, Kevin Appourchaux, Susruta Majumdar, Markus Muttenthaler, Parisa Hosseinzadeh, David J Craik, Mariana Spetea, Tao Che, David Baker, Christian W Gruber
Despite the increasing number of GPCR structures and recent advances in peptide design, the development of efficient technologies allowing rational design of high-affinity peptide ligands for single GPCRs remains an unmet challenge. Here, we develop a computational approach for designing conjugates of lariat-shaped macrocyclized peptides and a small molecule opioid ligand. We demonstrate its feasibility by discovering chemical scaffolds for the kappa-opioid receptor (KOR) with desired pharmacological activities...
December 6, 2023: Nature Communications
https://read.qxmd.com/read/38044924/efficacy-of-intravenous-nalbuphine-for-managing-post-anaesthesia-shivering-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials-with-trial-sequential-analysis
#70
JOURNAL ARTICLE
Abhijit Nair, Ujjwalraj Dudhedia, Manamohan Rangaiah, Suhrud Panchawagh
BACKGROUND AND AIMS: Post-anaesthesia shivering is distressing and is observed after spinal and general anaesthesia. Nalbuphine, a partial mu-opioid receptor antagonist with kappa-opioid receptor agonist properties, has been successfully used to manage post-anaesthesia shivering. METHODS: After registering the review with the International Prospective Register of Systematic Reviews (PROSPERO), we searched PubMed/Medline, Scopus, Ovid, Cochrane Library and clinicaltrials...
October 2023: Indian Journal of Anaesthesia
https://read.qxmd.com/read/38029388/a-balancing-act-learning-from-the-past-to-build-a-future-focused-opioid-strategy
#71
REVIEW
Sarah Warren Gooding, Jennifer L Whistler
The harmful side effects of opioid drugs such as respiratory depression, tolerance, dependence, and abuse potential have limited the therapeutic utility of opioids for their entire clinical history. However, no previous attempt to develop effective pain drugs that substantially ameliorate these effects has succeeded, and the current opioid epidemic affirms that they are a greater hindrance to the field of pain management than ever. Recent attempts at new opioid development have sought to reduce these side effects by minimizing engagement of the regulatory protein arrestin-3 at the mu-opioid receptor, but there is significant controversy around this approach...
February 12, 2024: Annual Review of Physiology
https://read.qxmd.com/read/38028425/the-opioid-receptor-emergence-through-millennia-of-pharmaceutical-sciences
#72
REVIEW
Carolyn A Fairbanks, Cristina D Peterson
Throughout history humanity has searched for an optimal approach to the use of opioids that maximizes analgesia while minimizing side effects. This review reflects upon the conceptualization of the opioid receptor and the critical role that the pharmaceutical sciences played in its revelation. Opium-containing formulations have been delivered by various routes of administration for analgesia and other therapeutic indications for millennia. The concept of a distinct site of opium action evolved as practitioners developed innovative delivery methods, such as intravenous administration, to improve therapeutic outcomes...
2023: Front Pain Res (Lausanne)
https://read.qxmd.com/read/38024852/monoclonal-antibody-targeting-mu-opioid-receptor-attenuates-morphine-tolerance-via-enhancing-morphine-induced-receptor-endocytosis
#73
JOURNAL ARTICLE
Jia-Jia Zhang, Chang-Geng Song, Miao Wang, Gai-Qin Zhang, Bin Wang, Xi Chen, Peng Lin, Yu-Meng Zhu, Zhi-Chuan Sun, Ya-Zhou Wang, Jian-Li Jiang, Ling Li, Xiang-Min Yang, Zhi-Nan Chen
Morphine is a frequently used analgesic that activates the mu-opioid receptor (MOR), which has prominent side effects of tolerance. Although the inefficiency of morphine in inducing the endocytosis of MOR underlies the development of morphine tolerance, currently, there is no effective therapy to treat morphine tolerance. In the current study, we aimed to develop a monoclonal antibody (mAb) precisely targeting MOR and to determine its therapeutic efficacy on morphine tolerance and the underlying molecular mechanisms...
October 2023: Journal of Pharmaceutical Analysis
https://read.qxmd.com/read/38018943/-how-can-ketamine-be-used-to-manage-suicidal-risk
#74
JOURNAL ARTICLE
Emilie Olié, Aisté Lengvenyte, Philippe Courtet
In France, suicidal behaviors remain a major public health issue. Depressed patients with suicidal ideation have more severe depressive symptoms, a more unfavorable disease course, and a greater number of suicide attempts than patients without suicidal ideation. Unfortunately, conventional antidepressants tend to be less effective in patients with suicidal tendencies than in those without. Nevertheless, promising advancements have emerged with the use of ketamine, which has shown significant and rapid efficacy in reducing the intensity of suicidal ideation in depressed patients within the first 72 h after its administration...
2023: Biologie Aujourd'hui
https://read.qxmd.com/read/38017066/functional-brain-region-specific-neural-spheroids-for-modeling-neurological-diseases-and-therapeutics-screening
#75
JOURNAL ARTICLE
Caroline E Strong, Jiajing Zhang, Martin Carrasco, Srikanya Kundu, Molly Boutin, Harshad D Vishwasrao, Jiamin Liu, Angelica Medina, Yu-Chi Chen, Kelli Wilson, Emily M Lee, Marc Ferrer
3D spheroids have emerged as powerful drug discovery tools given their high-throughput screening (HTS) compatibility. Here, we describe a method for generating functional neural spheroids by cell-aggregation of differentiated human induced pluripotent stem cell (hiPSC)-derived neurons and astrocytes at cell type compositions mimicking specific regions of the human brain. Recordings of intracellular calcium oscillations were used as functional assays, and the utility of this spheroids system was shown through disease modeling, drug testing, and formation of assembloids to model neurocircuitry...
November 28, 2023: Communications Biology
https://read.qxmd.com/read/38014065/cholinergic-mu-opioid-receptors-participate-in-nicotine-but-not-ethanol-drinking-behaviors
#76
Cambria R Beane, Kat L Pikus, Delainey G Lewis, Nicolaus Bruns, Mary H Durfee, Roman A Zegarelli, Thomas W Perry, Anna K Radke
Heavy alcohol use and binge drinking are important contributors to alcohol use disorder (AUD). The endogenous opioid system has been implicated in alcohol consumption and preference in both humans and animals. The mu opioid receptor (MOR) is expressed on multiple cells in the striatum, however little is known about the contributions of specific MOR populations to alcohol drinking behaviors. The current study used mice with a genetic deletion of MOR in cholinergic cells (ChAT-Cre/Oprm1 fl/fl ) to examine the role of MORs expressed in cholinergic interneurons (CINs) in home cage self-administration paradigms...
November 16, 2023: bioRxiv
https://read.qxmd.com/read/38005269/identification-and-pharmacological-characterization-of-a-low-liability-antinociceptive-bifunctional-mor-dor-cyclic-peptide
#77
JOURNAL ARTICLE
Yangmei Li, Shainnel O Eans, Michelle Ganno-Sherwood, Abbe Eliasof, Richard A Houghten, Jay P McLaughlin
Peptide-based opioid ligands are important candidates for the development of novel, safer, and more effective analgesics to treat pain. To develop peptide-based safer analgesics, we synthesized a mixture-based cyclic pentapeptide library containing a total of 24,624 pentapeptides and screened the mixture-based library samples using a 55 °C warm water tail-withdrawal assay. Using this phenotypic screening approach, we deconvoluted the mixture-based samples to identify a novel cyclic peptide Tyr-[D-Lys-Dap(Ant)-Thr-Gly] (CycloAnt), which produced dose- and time-dependent antinociception with an ED50 (and 95% confidence interval) of 0...
November 11, 2023: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38001914/additive-anticonvulsant-profile-and-molecular-docking-analysis-of-5-5-diphenylhydantoin-schiff-bases-and-phenytoin
#78
JOURNAL ARTICLE
Jana Tchekalarova, Petar Todorov, Miroslav Rangelov, Tsveta Stoyanova, Nadezhda Todorova
Four 5,5'-diphenylhydantoin Schiff bases possessing different aromatic species ( SB1 - SB4 ) were recently synthesized and characterized using spectroscopic and electrochemical tools. The present study aimed to ascertain the anticonvulsant activity of the novel phenytoin derivatives SB1-Ph , SB2-Ph , SB3-Ph , and SB4-Ph , containing different electron-donor and electron-acceptor groups, and their possible mechanism of action. The SB2-Ph exhibited the highest potency to suppress the seizure spread with ED50 = 8...
October 27, 2023: Biomedicines
https://read.qxmd.com/read/37996009/microglial-activation-and-toll-like-receptor-4-dependent-regulation-of-angiotensin-ii-type-i-receptor-mu-opioid-receptor-1-heterodimerization-and-hypertension-in-fructose-fed-rats
#79
JOURNAL ARTICLE
Chiu-Yi Ho, Gwo-Ching Sun, Yu-Te Lin, Tzyy-Yue Wong, Michael Hsiao, Ching-Jiunn Tseng, Pei-Wen Cheng
Our previous study reported that the heterodimer of Angiotensin II Type I Receptor (AT1R) and Mu-Opioid Receptor 1 (MOR1) involves Nitric Oxide (NO) reduction which leads to elevation of blood pressure. Secondly, we showed that Toll-like Receptor 4 (TLR4) may be involved in the heterodimerization of AT1R and MOR1 in the brainstem Nucleus Tractus Solitarii (NTS), which regulates systemic blood pressure and gastric nitric oxide through the insulin pathway. Here, we investigated the role of microglial activation and TLR4 in the heterodimerization of AT1R and MOR1...
November 22, 2023: European Journal of Pharmacology
https://read.qxmd.com/read/37985179/chronic-morphine-induces-adaptations-in-opioid-receptor-signaling-in-a-thalamo-striatal-circuit-that-are-location-dependent-sex-specific-and-regulated-by-mu-opioid-receptor-phosphorylation
#80
JOURNAL ARTICLE
Elizabeth R Jaeckel, Yoani N Herrera, Stefan Schulz, William T Birdsong
Chronic opioid exposure induces tolerance to the pain-relieving effects of opioids but sensitization to some other effects. While the occurrence of these adaptations is well-understood, the underlying cellular mechanisms are less clear. This study aimed to determine how chronic treatment with morphine, a prototypical opioid agonist, induced adaptations to subsequent morphine signaling in different subcellular contexts. Opioids acutely inhibit glutamatergic transmission from medial thalamic (MThal) inputs to the dorsomedial striatum (DMS) via activity at μ-opioid receptors (MORs)...
November 20, 2023: Journal of Neuroscience
keyword
keyword
60609
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.